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Cardiac hypertrophy entails complex structural remodeling involving rearrangement of muscle ﬁbers, interstitial ﬁbrosis, ac-
cumulation of extracellular matrix, and angiogenesis. Many of the processes underlying cardiac remodeling have features in
common with chronic inﬂammatory processes. During these processes, nonmyocytes, such as endothelial cells, ﬁbroblasts, and
immune cells, residing in or inﬁltrating into the myocardial interstitium play active roles. This paper mainly addresses the
functional roles of nonmyocytes during cardiac remodeling. In particular, we focus on the communication between cardiomyo-
cytes and nonmyocytes through direct cell-cell interactions and autocrine/paracrine-mediated pathways.
1.Introduction
Cardiachypertrophyisanessentialadaptiveprocess,through
which the heart responds to various mechanophysical, meta-
bolic, and genetic stresses. On the other hand, the hypertro-
phy induced by sustained overload eventually leads to con-
tractile dysfunction and heart failure. Cardiac hypertrophy
involvescellularandmoleculareventswithin bothcardiomy-
ocytes and nonmyocytes. Cardiomyocytes show phenotypic
modiﬁcation that results in cellular hypertrophy accompa-
nied by reexpression of several fetal genes, abnormal Ca2+
handling, oxidative stress and mitochondrial DNA damage,
and cardiomyocyte death due to necrosis or apoptosis [1].
In addition to cardiomyocytes, the myocardium contains a
variety of nonmyocytes, including vascular endothelial, and
smooth muscle cells, ﬁbroblasts and immune cells, which all
appear to be crucially involved in the myocardial response to
external and internal stress [2, 3]. During cardiac hypertro-
phy and the progression toheart failure, the myocardium ex-
hibits complex structural remodeling involving rearrange-
ment of muscle ﬁbers, ﬁbrosis, accumulation of extracellular
matrix (ECM), cellular death, and angiogenesis [4]. Many of
the processes underlying these phenomena are also seen in
chronic inﬂammatory diseases and are mediated by cellular
interactions among cardiomyocytes and nonmyocytes. In
this paper, we will focus on the functional roles of nonmy-
ocytes and the cellular communication ongoing during the
development of cardiac hypertrophy and heart failure under
noninfectiousandnoninfarctionconditions,suchaspressure
overload.
2.Fibroblasts
Cardiac ﬁbroblasts are critically involved in the development
of cardiac ﬁbrosis [4, 5]. They can produce a wide variety of
ECMproteins,includinginterstitial collagens,proteoglycans,
glycoproteins, and proteases [6]. Morphologically, ﬁbrob-
lasts are ﬂat, spindle-shaped cells with multiple processes
sprouted from the cell body, which lacks a basement
membrane [7]. Fibroblasts play central roles in two types
of ﬁbrosis: reparative and reactive. Reparative (replacement)
ﬁbrosis or scarring accompanies cardiomyocyte death. Reac-
tive ﬁbrosis appears as “interstitial” or “perivascular” ﬁbrosis2 International Journal of Inﬂammation
and does not directly associate with cardiomyocyte death
[8, 9].
Increases in ﬁbrosis result in mechanical stiﬀness and
cardiac diastolic dysfunction [10]. In addition, by forming a
barrier betweencardiomyocytes, ﬁbrosis canimpair theelec-
trical coupling of cardiomyocytes, leading to cardiac systol-
ic dysfunction [11]. Moreover, perivascular ﬁbrosis can in-
crease oxygen and nutrient diﬀusion distances, leading to
pathological remodeling [12]. Thus, ﬁbrosis profoundly af-
fects cardiomyocyte metabolism and performance, and ulti-
mately ventricular function [13]. However, the functions of
ﬁbroblasts are not limited to producing ECM. Cardiac ﬁbro-
blasts interact with other cell types, most notably cardiomy-
ocytes.This interactionmay bedirectviaphysicalcontactsor
indirectviaparacrine factors.Thus ﬁbroblastsareinvolvedin
much more than deposition of collagen [4, 7, 14].
In response to external stress, ﬁbroblasts change their
phenotype and become myoﬁbroblasts [15, 16], which ex-
press several smooth muscle (SM) markers, including SM α-
actin, SM22α, SMemb/nonmuscle myosin heavy chain-B,
and tropomyosin [16–18]. However, more stringent SM
markers (e.g., SM myosin heavy chains) are not expressed
in myoﬁbroblasts [19]. With the exception of heart valve
leaﬂets, myoﬁbroblasts are not found in normal cardiac tis-
sue [4].
So far, no common deﬁnitive ﬁbroblast-speciﬁc marker
that could be used to identify ﬁbroblasts in diﬀerent tis-
sues has been determined. In fact, ﬁbroblasts in diﬀerent
tissues likely diﬀer with respect to their cellular origins and
functions. Several markers have been used to identify cardi-
ac ﬁbroblasts. Discoidin domain receptor 2 (DDR2) is spe-
ciﬁcally expressed by ﬁbroblasts within the heart [20, 21],
and, in a recent report, was successfully used as a marker in
a ﬂow cytometric analysis of cardiac cells [22]. This study
found that ﬁbroblasts represent a substantial portion of the
cells in the mammalian heart. Forexample, the adult murine
heart consists of approximately 55% cardiomyocytes and
45% nonmyocytes (∼27% ﬁbroblasts), and the adult rat
heart consists of30% cardiomyocytesand 70% nonmyocytes
(∼67% ﬁbroblasts). Periostin [23] and thymus cell antigen-
1 (Thy1/CD90) [14, 24] also have been used as markers of
ﬁbroblasts in developing and adult hearts. However, because
ﬁbroblasts can acquire heterogeneous phenotypes [25–27],
those markers may not be capable of identifying all ﬁbrob-
lasts under all physiological and pathological conditions
[5, 28]. Commonly used ﬁbroblasts markers are reviewed
elsewhere [28].
2.1. Origin and Phenotype of Cardiac Fibroblasts. The major-
ity of resident cardiac ﬁbroblasts are thought to arise from
embryonic proepicardial organ (Figure 1)[ 23, 29]. Proepi-
cardial and primitive epicardial cells undergoepithelial-mes-
enchymal transition (EMT) and then migrate into the myo-
cardium, where they progressively diﬀerentiate into intersti-
tial ﬁbroblasts, perivascular ﬁbroblasts, and coronary SMCs
[30, 31]. These resident ﬁbroblasts have traditionally been
thought to be the sole source of cardiac ﬁbroblasts, but
more recently other cellular origins of cardiac ﬁbroblasts
have been proposed [23]. Endothelial cells and pericytes
may also contribute to cardiac ﬁbroblasts via endothelial-
to-mesenchymal transition (EndMT) and EMT, respectively
[32, 33]. In addition, bonemarrow-derived cells may acquire
ﬁbroblast-like phenotypes[32, 34–37], and ﬁbrocytes, circu-
lating mesenchymal progenitor cells of bone-marrow origin,
have been shown to be recruited to ischemic hearts and to
express SM α-actin, collagen I, vimentin, and DDR2 [38].
Finally, it has been suggested that monocytes/macrophages
represent another potential source of myoﬁbroblasts in is-
chemichearts [39].Howthesevariousbone-marrow-derived
cells are related to one another remains unclear, as does
their precise lineage origins, in part, because of a lack of
deﬁnitive markers for ﬁbroblasts and the diﬀerent myeloid
cell subsets. Macrophages may also promote ﬁbrosis by
producing cytokines, such as TGF-β. It is therefore likely
thatbone-marrow-derived cellsplaymultiplerolesin cardiac
ﬁbrosis. Further studies will be needed to clarify precisely
how these cells contribute to cardiac ﬁbrosis.
2.2. Mediators of Intercellular Communications in Fibrogenic
and Cardiomyocyte Hypertrophic Responses. Cardiomyocyte-
speciﬁc deletion of genes has been shown to aﬀect not
only cardiomyocyte functionality but also the phenotypes
and functions of ﬁbroblasts [4]. Conversely, recent studies
have shown that cardiac ﬁbroblasts control cardiomyocyte
proliferation in the developing ventricles during embry-
ogenesis and that ﬁbroblasts promote cardiomyocyte hyper-
trophy through paracrine factors and ECM [14, 24, 40].
These ﬁndings are indicative of the communication between
cardiomyocytes andﬁbroblasts. Herewe describe factors that
mediate intercellular communication within the myocardi-
um (Figure 2).
2.2.1. Angiotensin II. Ang II is a pleiotropic vasoactive pep-
tidethatplayskeyrolesinthedevelopmentofcardiacﬁbrosis
and remodeling. Although most of the cardiovascular eﬀects
of Ang II are mediated via the Ang II type 1 receptor (AT1),
the Ang II type 2 receptor (AT2) may be also important,
as expression of both receptors is upregulated in various
cardiac diseases [41–43]. Continuous infusion of Ang II
into mice induces cardiac hypertrophy and ﬁbrosis [44, 45].
Under these conditions, most of the proliferating ﬁbro-
blasts were found to be surrounding cardiomyocytes carry-
ing the AT1a receptor [46], suggesting that activation of car-
diomyocytes via AT1a receptors also aﬀects ﬁbroblasts. Ang
II also stimulates paracrine release of growth factors and
cytokines, including TGF-β1 and endothelin-1 (ET-1) from
cardiomyocytes [47–49]. On the other hand, AT1 receptor
expression is greater in ﬁbroblasts than cardiomyocytes
[47], and Ang II directly stimulates ﬁbroblast proliferation,
collagen and ECM synthesis, and expression of ﬁbroblast
growth factor 2 (FGF2) [50]. It therefore seems likely
that reciprocal interactions between cardiomyocytes and
ﬁbroblasts viaparacrine factors areimportant for myocardial
responses toAngII.Consistent withtheseinvitroandinvivo
ﬁndings in animal models are recent clinical studies dem-
onstrating that blockade of the rennin-angiotensin system
in patients, using a direct renin inhibitor, an angiotensin
converting enzyme inhibitor, or an angiotensin receptorInternational Journal of Inﬂammation 3
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Figure 1: Diverse origins of cardiac ﬁbroblasts. Resident cardiac ﬁbroblasts are thought to arise from the proepicardium and embryonic
epicardium during development. In response to ﬁbrogenic stimuli, however, many other cell types, including bone marrow-derived cells,
pericytes, and endothelial cells, may also acquire myoﬁbroblast-like phenotypes. This scheme depicts the possible origins of cardiac
ﬁbroblasts. EMT: epithelial-to-mesenchymal transition; EndMT: endothelial-to-mesenchymal transition.
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Figure 2: Reciprocal interactions between ﬁbroblasts and cardiomyocytes. Many growth factors and cytokines have been shown to act in
autocrine and/or paracrine fashion to induce hypertrophic responses in cardiomyocytes and activate ﬁbroblasts. This scheme depicts only
some of the factors identiﬁed. Ang II: angiotensin II; TGF-β: transforming growth factor-β; PDGF: platelet-derived growth factors; IGF-1:
insulin-likegrowthfactor-1;CT-1:cardiotrophin-1;LIF:leukemiainhibitoryfactor;FGF-2:ﬁbroblastgrowthfactor2;ANP:atrialnatriuretic
peptide; BNP: brain natriuretic peptide; IL-33: interleukin-33; ECM: extracellular matrix; OPN: osteopontin; FBN: ﬁbronectin.
blocker, eﬀectively reduces cardiac ﬁbrosis and remodeling
in addition to reducing blood pressure [51].
AT2 receptor expression is also upregulated in failing
human hearts, mainly in cardiac ﬁbroblasts [43, 52]; how-
ever,thefunction ofAT2remains controversial.Initially, AT2
was reported to mediate eﬀects opposing the growth-pro-
moting signals mediated by AT1 [53], but since then there
have been several reports that AT2 also stimulates prohy-
pertrophic signaling [54, 55]. The function of AT2 may de-
pend on the adaptor proteins recruited to the receptor and
the pathophysiological conditions [56, 57].
2.2.2. Transforming Growth Factor-β. TGF-β exists in three
isoforms (TGF-β1, TGF-β2, and TGFβ-3) that have distinct
but overlapping functions in immunity, inﬂammation, and
tissue repair, and TGF-β also has a central role in ﬁbroblast
activation and diﬀerentiationinto myoﬁbroblasts [58]. TGF-
β is initially produced as a latent complex bound to latent
TGF-β binding protein (LTBP) within the interstitium. It
is activated physiochemically by altered pH, a large group
of proteases and enzymes, high-energy ionizing radiation,
or integrin-mediated mechanisms [59, 60]. Activated TGF-β
binds to heterodimers comprised of TGF-β type 1 receptor4 International Journal of Inﬂammation
(TGF-βR1) and type 2 receptor (TGF-βR2) on both car-
diomyocytes and ﬁbroblasts [61]. TGF-βR1 (ALK5; activin-
linked kinase 5) then phosphorylates receptor-regulated
Smads (R-Smads: Smad2 and Smad3), which in turn asso-
ciatewith acommon-mediator Smad(co-Smad:Smad4)and
are translocated into the nucleus, where they act as tran-
scription factors [62].Smad3isrequiredforTGF-β toinduce
expression of collagen, ﬁbronectin, and other ECM genes
[63–66].
TGF-β promotes myoﬁbroblast diﬀerentiation and ECM
productionbyﬁbroblasts,andAngII-inducedcardiachyper-
trophy is also mediated in part through TGF-β secreted
from AT1-expressing ﬁbroblasts [47].TGF-β1-deﬁcientmice
subjected to chronic subpressor doses of Ang II showed no
signiﬁcant cardiac hypertrophy or ﬁbrosis [67], which sug-
gests that strategies to block TGF-β signaling may be use-
ful for treating ﬁbrogenic cardiac remodeling. Indeed, a
TGF-β neutralizing antibody inhibited ﬁbroblast activation
and proliferation, and diastolic dysfunction in pressure-
overloaded rats[68]. Similarly, an ALK5 inhibitor attenuated
ﬁbroblast activation and systolic dysfunction in an experi-
mental rat model of myocardial infarction [69]. However,
ﬁbrosis was attenuated in Smad3-diﬁcient mice subjected to
experimental cardiac pressure overload, cardiac hypertrophy
and heart failure were aggravated [70]. Moreover, TGF-β
neutralizing antibody increased mortality and worsened car-
diac remodeling, which correlated with reduction of ECM
in a rat MI model [71]. These results indicate that the con-
sequences of inhibiting TGF-β signaling can vary depend-
ing on the disease model and the timing of the inhibi-
tion, presumably because TGF-β signaling has an essential
adaptive role in the myocardium under stress. Seemingly
maladaptive functions, such as ﬁbrosis, might also be essen-
tial for adaptation in other contexts. It will, therefore, be
important to clarify the spatiotemporal functions of TGF-
β signaling in diﬀerent disease contexts if we are to develop
eﬀective therapeutic approaches involving TGF-β.
2.2.3. Fibroblast Growth Factor-2. FGF-2 is alternatively
translated as a high molecular weight (Hi-FGF-2) and a
low molecular weight (Lo-FGF-2) isoform from the single
Fgf2 gene [72]. The Hi-FGF-2 isoform contains nuclear
localization sequences and is found predominantly within
the nucleus, while the Lo-FGF-2 isoform is localized in the
ECM and cytoplasm[72]. Cardiac ﬁbroblastspredominantly
express Hi-FGF-2, which acts in a paracrine fashion to pro-
motecardiomyocytehypertrophy[49]. Hi-FGF-2also acts in
an autocrine fashion on the ﬁbroblasts themselves to stim-
ulaterelease ofotherpro-hypertrophic factors, such as cardi-
otrophin-1 (CT-1) [49, 73, 74]. In addition, Lo-FGF-2 elic-
its cardioprotective eﬀects against postischemic cardiac dys-
function [72].
2.2.4. Interleukins. The IL-6 family of cytokines, including
leukemia inhibitory factor (LIF) and CT-1, are expressed
by cardiac ﬁbroblasts and cardiomyocytes. LIF and CT-1
secreted from ﬁbroblasts mediate Ang II-induced cardiom-
yocyte hypertrophy [75, 76]. LIF was also shown to induce
ﬁbroblast hypertrophy but to inhibit myoﬁbroblast transi-
tion and collagen deposition [77].
IL-33 is produced primarily by cardiac ﬁbroblasts, and
its expression is upregulated by cyclic strain [78]. IL-33
binds to a transmembrane form of the ST2 receptor (ST2L)
on cardiomyocytes and inhibits the hypertrophic response
of cultured cardiomyocytes to pro-hypertrophic stimuli. In
vivo, IL-33 inhibits cardiomyocyte hypertrophy as well as
ﬁbrosis induced by pressure overload [40, 79].
2.2.5. Serotonin. Serotonin (5-hydroxytryptamine [5-HT])
acts via its 5-HT2B receptor (5-HT2BR) to contribute to
cardiac hypertrophy. Indeed, plasma serotonin levels and
cardiac 5-HT2BR expression are both elevated in human
heart failure. 5-HT2BRsmainly colocalize with AT1 receptors
in ﬁbroblasts [80, 81]. Isoproterenol (ISO) and Ang II-
induced cardiac hypertrophy is suppressed in 5-HT2BR-def-
icient mice, and this eﬀect is accompanied by reduced pro-
duction of cytokines (IL-6, IL-1β,T G F - β,a n dT N F - α)a n d
reactive oxygen species in cardiac ﬁbroblasts [82, 83]. Simi-
larly, pharmacological blockade of 5-HT2BRs prevents ISO-
induced murine cardiac hypertrophy [82]. Moreover, mice
in which expression of 5-HT2BR is limited to their cardiomy-
ocytes are also resistant to ISO-induced cardiac hypertrophy
and dysfunction, as well as to ISO-induced upregulation
of the cytokines. This suggests that signaling through 5-
HT2BRs on ﬁbroblasts stimulates production of cytokines
that promote cardiomyocyte hypertrophy [81, 84].
2.2.6. Platelet-Derived Growth Factors. PDGF-A and -B are
secreted from cardiomyocytes and ﬁbroblasts and play crit-
ical roles in cardiac ﬁbrosis and angiogenesis through their
interactions with theprotein tyrosine kinase receptors PDGF
receptor (PDGFR)-α and -β [85, 86]. PDGF signaling acti-
vates ﬁbroblast proliferation and migration and ECM depo-
sition. PDGF expression is signiﬁcantly increased in cardiac
hypertrophy and ﬁbrosis [87], atrial ﬁbrillation [88], and
chronic rejection of cardiac allografts [89]. PDGF-C and
-D may also contribute to cardiac ﬁbrosis and remodeling.
Transgenic mice exhibiting cardiomyocyte-speciﬁc expres-
sion of PDGF-C and -D develop hyperproliferation of myo-
cardial interstitial cells, resulting in progressive ﬁbrosis lead-
ing to dilated cardiomyopathy and heart failure [90–92].
PDGF signaling has been assessed as a therapeutic target
for cardiac remodeling. The synthetic retinoid Am80 inhib-
ited upregulation of PDGF-A by inhibiting the transcription
factor Kr¨ uppel-like factor 5 (KLF5), thereby suppressing
Ang II-induced cardiac ﬁbrosis (Figure 3)[ 87, 93]. In addi-
tion, a neutralizing PDGFRα-speciﬁc antibody attenuated
induction of pressure overload-induced atrial ﬁbrosis and
ﬁbrillation [88]. However, several inhibitors of receptor
tyrosine kinases, including PDGFRs, have been linked to the
development of cardiomyopathy in some treated patients
[94–97]. PDGFR-β on cardiomyocytes is indispensable for
the cardiac response to pressure overload and may regulate
angiogenesis [98]. For therapies targeting PDGF signaling to
cardiac remodeling, it will be important to further clarify the
precise roles played by PDGFs and PDGFRs under various
pathological and physiological conditions.International Journal of Inﬂammation 5
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Figure 3:A modelfor theregulation ofﬁbroblasts by KLF5dur-ing
cardiac hypertrophy. The transcription factor KLF5 controls Igf1
and Pdgfa expression in cardiac ﬁbroblasts. IGF-1 is a major cardi-
otrophic factor secreted from ﬁbroblasts, and PDGF-A is primarily
involvedinmediatingthemigrationandproliferationofﬁbroblasts.
2.2.7. Insulin-Like Growth Factor-1. IGF-1 exerts adaptive
and cardioprotective eﬀects in response to stress. The major-
ity of serum IGF-1 is liver-derived and plays a critical
role during normal body development. However, postnatal
body growth is preserved, even in the complete absence of
IGF-1 expression by hepatocytes; autocrine/paracrine IGF-1
appears to have important regulatory functions under these
conditions [99]. In the heart, IGF-1 is mainly expressed
in cardiac ﬁbroblasts [14] and activates downstream signal
transducers, such as phosphoinositide 3-kinase (PI3K),lead-
ing to cardiomyocyte hypertrophy [100]. We recently found
that cardiac IGF-1 is transactivated by KLF5 (Figure 3)[ 14].
Although cardiac ﬁbroblast-speciﬁc deletion of Klf5 amel-
iorated the cardiac hypertrophy and ﬁbrosis elicited by mod-
erate-intensity pressure overload, it resulted in severe heart
failure in high-intensity pressure overload. Similarly, admin-
istration of a peptide inhibitor of IGF-1 severely exacerbated
heart failure induced by high-intensity pressure overload.
Theseﬁndings indicatethatinductionofIGF-1isanessential
cardioprotective response; that cardiac ﬁbroblasts play a piv-
otal role in the myocardial adaptive response to pressure
overload; that KLF5 controls IGF-1 expression in cardiac
ﬁbroblasts in response to stress [14].
2.2.8. Connective Tissue Growth Factor. CTGF (also known
as CCN2) is expressed in ﬁbroblasts and cardiomyocytes and
regulates ECM deposition and wound healing [101, 102].
CTGFisinducedbyTGF-β,A ngII,andET -1.B yitself,CT GF
only weakly promotes ﬁbrosis and cardiomyocyte hypertro-
phy, but it appears that it may promote a more robust eﬀect
by acting as a cofactor for TGF-β [103, 104]. Transgenic mice
exhibiting cardiomyocyte-speciﬁc expression of CTGF did
not develop cardiac hypertrophy or ﬁbrosis under baseline
conditions but showed signiﬁcantly increased ﬁbrosis and
contractile dysfunction in response to pressure overload
[105]. Another group of transgenic mice developed age-
dependent cardiac hypertrophy and dysfunction, though
Ang II did not increase ﬁbrosis in young transgenic mice
[106]. Thus, the cardiac actions of CTGF will require further
study.
2.2.9. Natriuretic Peptides. Atrial natriuretic peptide (ANP)
and brain natriuretic peptide (BNP) are usually synthesized
intheatria andventricles,respectively [107].Plasma levelsof
these peptide hormones are widely used as biomarkers when
making a diagnosis or determining risk stratiﬁcation in a
variety of cardiac disease states. In addition, infusion of syn-
thetic ANP or BNP is useful for treating cardiac heart failure
and remodeling, mainly by optimizing intravascular volume
and arterial pressure [108]. ANP and BNP also exert anti-
hypertrophic and antiﬁbrogenic eﬀects on the heart, and
knockout mice deﬁcient in their common receptor, guan-
ylyl cyclase-A (GC-A), showed cardiac hypertrophy and ex-
tensive interstitial ﬁbrosis that was at least partially inde-
pendent of blood pressure [109–111]. In ﬁbroblasts, BNP
inhibits TGF-β-regulated genes related to ﬁbrosis (collagen
I, ﬁbronectin, and CTGF), proliferation (PDGF-A and IGF-
1), and inﬂammation (COX2, IL-6, and TNF) [112], while
ANPsuppresses ET-1 expression and cell proliferation[113].
This suggests ANP and BNP secreted from cardiomyocytes
suppress the ﬁbrogenic activity of ﬁbroblasts.
2.2.10. ECM Molecules. ECM serves as an important inter-
mediary for intercellular communication by transducing in-
tracellular signals via its receptor molecules (integrins and
CD44)onmyocardialcells[24,114–116].Production,degra-
dation and modiﬁcation of ECM components are dynam-
ically regulated under both physiological and pathological
conditions. Fibroblasts are a major source of nonbasement
membrane collagen and other ECM proteins, and other cells
in the myocardium, including cardiomyocytes, endothelial
cells, and SMCs, also produce sets of ECM components
[117]. Cardiac ﬁbroblasts and macrophages are major pro-
ducers of matrix metalloproteases (MMPs), which degrade
ECM proteins.
The integrin family consists of 18 α and 8 β subunits,
which form 24 known α-β-heterodimers. Integrins serve as
cell-ECM and cell-cell adhesion molecules and also function
as signal-transducing receptors for ECM proteins, includ-
ing collagen, laminin, ﬁbronectin (FBN), and osteopontin
(OPN) [116, 118]. Cardiac-speciﬁc integrin signaling in ge-
netically engineered animal models are reviewed elsewhere
[116].
CD44 was originally described as a receptor for hyaluro-
nan (HA), a ubiquitous constituent of the ECM, but is now
known to interact with collagen, laminin, FBN, and OPN
[119].CD44-HAinteractionsplayan important role inregu-
lating leukocyte extravasation into sites of inﬂammation and
in mediating eﬃcient phagocytosis. CD44 also contributes
to the resolution ofinﬂammation through removal ofmatrix
breakdownproducts,clearanceofapoptoticneutrophils,and
ﬁbroblast migration [120]. In injured hearts, CD44 is upreg-
ulated in ﬁbroblasts, leukocytes, and endothelial cells, par-
ticularly those cells surrounding and within the coronary
arteries [120,121].Cd44-deﬁcientmice subjectedtomyocar-
dial infarction show increased myocardial inﬁltration by
leukocytes and expression of proinﬂammatory cytokines,6 International Journal of Inﬂammation
followed by decreased ﬁbroblast inﬁltration and ﬁbrosis and
enhanced dilative cardiac remodeling [120]. Finally, Cd44-
deﬁcient cardiac ﬁbroblasts exhibit diminished proliferation
and collagen synthesis in response to TGF-β. This suggests
CD44 is important for resolution of postinfarction inﬂam-
matory processes and for regulation of ﬁbroblast function.
FBN and OPN are upregulated in cardiac hypertrophy
and by Ang II. They contain the arginine-glycine-aspar-
tate (RGD) tripeptide integrin binding motif and activate
integrin-mediated proliferation, survival, adhesion, diﬀeren-
tiation, and migration of myocardial cells [122–124]. FBN
is mainly expressed in ﬁbroblasts and acts in a paracrine
fashion to regulate cardiomyocyte proliferation through β1
integrinsignalingduringembryonicheartdevelopment[24].
OPN is strongly expressed in chronic inﬂammatory and
autoimmune diseases and promotes the recruitment and
retention of macrophages and T cells at inﬂamed sites [125].
Cardiomyocyte-speciﬁc overexpression of OPN results in
dilated cardiomyopathy and severeﬁbrosis, with recruitment
of activated T cells showing Th1 polarization [125]. More-
over, OPN (Spp1)-deﬁcient ﬁbroblasts are less proliferative
and less adherent to ECM substrates, while Spp1-deﬁcient
mice exhibit less Ang II-induced cardiac ﬁbrosis [123, 126].
Recently, OPN has emerged as a novel biomarker of various
cardiac diseases [127–129].
Periostinisprimarily expressed inmyocardial ﬁbroblasts,
and its expression is upregulated by pressure overload and
myocardial infarction. Periostin can serve as a ligand for
αvβ3, αvβ5, and α4β6 integrins [23]a n dc a na l s od i r e c t l y
interact with other ECM proteins, including FBN, tenascin-
C,collagenI/V,andheparin[130].Collagenﬁbrilsfromperi-
ostin (Postn)-null mice are reduced in size, somewhat disor-
ganized, and less eﬃciently cross-linked, indicating that per-
iostin facilitates proper organization of the ECM [23, 131,
132]. In addition, periostin is induced via TGF-β signaling
and may then enable collagen realignment in response to
TGF-β [130, 133, 134]. Postn-deﬁcient hearts subjected to
pressure overload or ischemic insult exhibited less ﬁbrosis
but more frequent rupture of the ventricular wall [132, 135].
3.EndothelialCells
Vascular endothelial cells are also crucially involved in the
development of cardiac hypertrophy, remodeling, and fail-
ure. Endothelial cells are capable of producing a wide variety
offunctionalagonistsandantagonists,includingvasodilators
and vasoconstrictors, procoagulants and anticoagulants, and
inﬂammatory and anti-inﬂammatory factors. Endothelial
cells maintain homeostasis by controlling the balance of
these various mediators [136]; endothelial dysfunction dis-
turbs that balance and leads to pathological inﬂammatory
processes. For instance, activated endothelial cells express
the adhesion molecules, intercellular adhesion molecule-1
(ICAM-1)and vascularcelladhesionmolecule-1(VCAM-1),
which recruit and promote the inﬁltration of immune cells
into the myocardium in response to various stimuli.
Endothelial cell-derived nitric oxide (NO), produced
by endothelial NO synthase (eNOS), is a key regulator of
vasodilation. NO also reduces vascular permeability and
thrombogenesis, and it inhibits inﬂammation by suppress-
ing signaling by adhesion molecules, proinﬂammatory cy-
tokines, and NF-κB[ 136]. Under pathological conditions,
thebioavailabilityofNOisdiminished [137,138].Forexam-
ple, sustained pressure overload triggers eNOS uncoupling,
which reduces NO signaling, increases levels of eNOS-de-
rived reactive oxygen species, and promotes endothelial dys-
function. NO is also known to inﬂuence myocardial exci-
tation-contraction coupling, substrate metabolism, and hy-
pertrophy, as well as cell survival, which are at least in
part dependent on eNOS and nNOS expression in cardiom-
yocytes [139]. For example, eNOS (Nos3)k n o c k o u tm i c e
develop concentric left ventricular hypertrophy and ﬁbrosis
[140], indicating the importance of the autocrine and
paracrine eﬀects of NO in cardiac remodeling.
Accumulating evidence indicates that impaired angio-
genesis contributes to the transition of cardiac hypertrophy
to heart failure. Hypertrophic stimuli induce expression of
the angiogenic growth factors, vascular endothelial growth
factor (VEGF), and angiopoietin 2 [141], which promote
angiogenesis and blood ﬂow in response to reductions
in coronary perfusion pressure or ischemia. Blockade of
VEGF action using an adenoviral vector encoding a decoy
VEGF receptor or an anti-VEGF antibody promotes the
transition from compensatory cardiac hypertrophy to failure
inresponse topressureoverloadinmice[142,143].Likewise,
TNP-470, an inhibitor of angiogenesis, also induced cardiac
dysfunction [144]. Conversely, VEGF treatment during
prolonged pressure overload preserved contractile function
[144, 145].
Within myocardium subjected to pressure overload,
hypoxia-inducible factor-1-(HIF-1-) mediated transactiva-
tion of VEGF in cardiomyocytes plays an important role
during induction of angiogenesis. Furthermore, it has been
proposed that, in response to sustained pressure overload,
p53accumulatesin cardiomyocytesand inhibitsHIF-1activ-
ity, thereby impairing cardiac angiogenesis and contractile
function [144]. However, there are also conﬂicting data
showing that ventricular deletion of HIF-1α prevents hy-
pertrophy-induced activation of peroxisome proliferator-
activated receptor-(PPAR-) γ and contractile dysfunction
[146].
Endothelin-1 (ET-1) is a major growth factor secreted
from endothelial cells that contributes to cardiac hypertro-
phy and ﬁbrosis. ET-1 was originally identiﬁed as an endo-
thelium-derived vasoconstrictor [147], but it is also express-
ed in various nonendothelial cells, including ﬁbroblasts and
cardiomyocytes, and it exerts both autocrine and paracrine
eﬀects that appear to be important for cardiomyocyte
hypertrophy [47, 48, 148]. Although cardiomyocytes pre-
dominantly express ETA ET-1 receptors, thehypertrophic re-
sponse to Ang II and ISO is unaltered in cardiomyocyte-
speciﬁc ETA receptor-(Ednra-) deﬁcient mice, suggesting
the possible involvement of ETA receptors on nonmyocytes
and ETB receptors in cardiomyocyte hypertrophy [48, 149].
Consistent with that idea, the combined ETA/ETB receptor
antagonist bosentan inhibited Ang II-inducedcardiac hyper-
trophy [150]. It was also shown that endothelium-derived
ET-1 promotes cardiac ﬁbrosis in diabetic heart [151].International Journal of Inﬂammation 7
4.Immune Cells
A variety of immune cells, including macrophages, T cells,
and mast cells, reside in the myocardium under physiolog-
ical conditions. They are also induced to inﬁltrate the myo-
cardium under pathogenic conditions and to promote car-
diac remodeling, in part by releasing cytokines, growth fac-
tors, and MMPs [152, 153].
Macrophages are essential eﬀector cells involved in tissue
remodeling and ﬁbrosis. It is becoming increasingly clear
that macrophages can have diverse phenotypes and func-
tions [154]. In vitro studies have shown that Th1 cytokines,
alone or in contact with microbial products, elicit classical
M1 activation of macrophages, which then release proin-
ﬂammatory cytokines and reactive oxygen species. Th2 cy-
tokines (IL-4 and IL-13) elicit an alternative form of
macrophage activation designated M2. M2 macrophages are
thought to suppress immune responses and promote ﬁbrosis
and tissue remodeling, though M2 activation is a rather
generic term often used to describe any form of macrophage
activation other than classical M1. Previous studies have
shown thatmacrophagesare involvedin cardiachypertrophy
and remodeling. Forinstance, Ang II-induced cardiac hyper-
trophy and ﬁbrosis were diminished in macrophage-speciﬁc
mineralocorticoid receptor-(MR-) deﬁcient mice [155]. The
MR-deﬁcientmacrophagesexhibitedM2-typeactivationand
reduced expression of proinﬂammatory cytokines, suggest-
ingitisM1-typemacrophagesthatareinvolvedinthecardiac
hypertrophy and ﬁbrosis induced by Ang II. Similarly, a
monoclonal neutralizing anti-MCP-1 antibody attenuated
not only macrophage accumulation, but also ﬁbroblast pro-
liferation and ﬁbrosis, resulting in amelioration of cardiac
diastolic dysfunction [156]. These results demonstrate the
pathological involvement of macrophages in cardiac hyper-
trophy and ﬁbrosis. By contrast, macrophage depletion us-
ingliposomal clodronateinducesabundantinﬁltration ofin-
ﬂammatory cells, predominantly CD4+ lymphocytes, and
aggravates cardiac dysfunction in hypertensive rats harbor-
ing the mouse renin gene (Ren2)[ 157]. This suggests
macrophages exert a protective eﬀect against cardiac dys-
functioninducedbyhypertension. Clearlyfurtherstudiesare
needed to clarify the seemingly diverse functions of macro-
phages in cardiac hypertrophy and heart failure. It is very
likely that macrophage function changes with time and in
diﬀerent pathological contexts [158]. It will therefore be
important to characterize the diﬀerentfunctions and pheno-
types of macrophages at diﬀerent times during the processes
of cardiac hypertrophy and heart failure and to elucidate
the underlying molecular mechanisms. These studies will be
essential for the development of novel therapeutic interven-
tions aﬀecting macrophages.
Mast cells reside in the myocardium, and their numbers
are increased in hypertrophied and failing hearts. Mast cells
are an important source of an array of cytokines, growth
factors,chemokines,andothermediators.Histamineisama-
jor mediator released upon mast cell degranulation in the
heart and may be involved in heart failure. Consistent
with that idea, inhibition of histamine using the histamine
H2 receptor antagonist famotidine reportedly ameliorates
heart failure [159, 160]. In addition, mast cells secrete the
proteases renin and chymase, which, respectively, catalyze
the conversion of angiotensinogen to angiotensin I and
angiotensin I to Ang II and may thus activate the local
rennin-angiotensin system in the heart [161]. Mast cell
degranulation also releases preformed TGF-β,P D G F - A ,
and TNF-α [88, 161, 162], and inhibition of mast cells
suppressescardiac dysfunctionand atrial ﬁbrillationinduced
by pressure and volume overload [88, 163]. These results
strongly suggest that mast cells are involved in inﬂammatory
processes that contribute to remodeling in the heart.
T cells also reside in the myocardium. Although little is
known about their function in cardiac pathology, Kvakan et
al. recently reported that adoptive transfer of CD4+ CD25+
regulatoryTcellssuppressescardiachypertrophyandﬁbrosis
induced by Ang II in mice, and this eﬀect was accompanied
by a marked reduction in inﬁltration of inﬂammatory cells
[164].
5.CardiacProgenitorCells
In addition to ﬁbroblasts and immune cells, the cardiac
stroma contains a number of mesenchymal cell types. Previ-
ous studies have demonstrated that a fraction of these mes-
enchymal cells,referred toascardiacprogenitorcells(CPCs),
have the potential to diﬀerentiate into cardiomyocytes under
certain conditions [165]. There is also some evidence of
cellular interactions between CPCs and their surrounding
cells, including cardiomyocytes and ﬁbroblasts. For instance,
IGF-1 and Ang II produced by surrounding cells aﬀect the
survival of CPCs [166, 167]. In addition, human CPCs were
shown to be connected to cardiomyocytes and ﬁbroblasts via
gap junctions and adherens junctions [168, 169], which may
enable cellular communication via mediating molecules,
includingmiRNA[170].CommunicationbetweenCPCsand
surrounding cells through Notch-Notch ligand and Eph-
ephrinsignalinghasalsobeenshown[171,172].Assuch,cel-
lular communication between mesenchymal cells, including
CPCs, and their surrounding cells, including cardiomyocytes
and ﬁbroblasts, may contribute to the myocardial response
to injury.
6.Conclusions
Bothcardiomyocytesand nonmyocytesplayessential rolesin
the processes involved in the development of cardiac hyper-
trophy, remodeling, and failure. The cellular and molecular
processes that contribute to cardiac remodeling and failure
share many features with chronic inﬂammatory processes in
other tissues. Thus sterile stresses such as pressure overload
and Ang II appear to activate pathways that are commonly
used in inﬂammatory processes, including those involving
immune cells in the myocardium. As we have seen here,
dynamic cellular interactions among cardiomyocytes and
nonmyocytes are a driving force for these inﬂammatory
processes. In that regard, it will be important to further
clarify the functional involvement of the diﬀerent cell types
residing in the myocardium and the underlying molecular
control mechanisms. The function of a particular cell type8 International Journal of Inﬂammation
may change with time and in response to diﬀerent insults.
As discussed, the functions of some myocardial cells, such as
ﬁbroblasts and macrophages, appear maladaptive under cer-
tain conditions but are in fact essential for adaptive respons-
es at diﬀerent times and in diﬀerent disease models. Elucida-
tion of these complex processes could lead to identiﬁcation
of novel therapeutic targets for the treatment of cardiac
hypertrophy and heart failure.
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